Internal Medicine Doctors in Edmond, OK Accepting Medicare

49 Internal Medicine doctors found. Showing 41 - 49

Dr. Nathaniel Weber, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 16400 N May Ave, Edmond, OK 73013 Phone: 405-471-6800    Fax: 405-471-6811

Mark Allen Hulsey, M.D. Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1701 Renaissance Blvd Ste 110, Edmond, OK 73013 Phone: 405-844-4978    Fax: 405-844-0562

Dr. Sanjaykumar Jagdishbhai Hapani, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 13301 N Meridian Ave, Suite 501, Edmond, OK 73120 Phone: 405-752-0872    Fax: 405-755-9510

Tanna Marie Shaw, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 15318 N May Ave Ste B, Edmond, OK 73013 Phone: 405-970-8020    Fax: 405-970-8025

Gus Anthony Gonzalez, MD Internal Medicine - Medical Oncology Medicare: Medicare Enrolled Practice Location: 701 Falling Sky Dr, Edmond, OK 73034 Phone: 417-544-4147

Dr. Jeremy Cole, MD Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 105 S Bryant Ave, Suite 204b, Edmond, OK 73034 Phone: 405-844-5200

Nishith Naveena Chandra Alva, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4801 Integris Pkwy, Edmond, OK 73034 Phone: 405-657-3120    Fax: 405-657-3122

Dr. Vijay N Prabhu, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 105 S Bryant Ave, Suite 200, Edmond, OK 73034 Phone: 405-340-4937    Fax: 405-341-3078

Jesse R. Campbell, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1575 N Santa Fe Ave, Edmond, OK 73003 Phone: 405-285-0660    Fax: 405-285-0659

News Archive

Researchers discover camelid-derived two nanobodies that target SARS-CoV-2

A new study has been published on the bioRxiv* preprint server, which has identified and characterized two RBD-targeting neutralizing nanobodies, namely, DL4 and DL28.

Advances in RNA research could pave new way for development of anti-cancer drugs

An international research team led by the University of Leicester has made a breakthrough advance that could pave a new route for the development of anti-cancer drugs.

iRhythm Technologies closes $17 million Series E financing

iRhythm Technologies, Inc., a healthcare information services company, today announced that it closed a $17 million Series E financing led by Novo A/S, a global life science investment firm.

miR-200 supression shifts primary lung cancer to metastatic disease

Primary lung cancer shifts to metastatic disease by suppressing a family of small molecules that normally locks the tumor in a noninvasive state, researchers at The University of Texas M. D. Anderson Cancer Center report in the Sept. 15 edition of Genes and Development.

J&JPRD receives FDA Complete Response Letter for ceftobiprole

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for ceftobiprole. The New Drug Application (NDA) was originally submitted to the FDA in May 2007 for the treatment of complicated skin and skin structure infections (cSSSI), including diabetic foot infections.

Read more Medical News

› Verified 6 days ago

• 1
• 2
• 3(current)